Product Name :
TTP-8307
Description:
TTP-8307 is a potent inhibitor of the replication of several rhino- and enteroviruses. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC50=1.2 μM) and poliovirus by interfering with the synthesis of viral RNA. TTP-8307 exerts antiviral activity through oxysterol-binding protein (OSBP).
CAS:
950225-08-8
Molecular Weight:
436.48
Formula:
C27H21FN4O
Chemical Name:
N-[(1R)-1-(4-fluorophenyl)ethyl]-3-[2-(isoquinolin-3-yl)-1H-imidazol-5-yl]benzamide
Smiles :
C[C@@H](NC(=O)C1=CC(=CC=C1)C1=CN=C(N1)C1=CC2=CC=CC=C2C=N1)C1C=CC(F)=CC=1
InChiKey:
SIBDJDZVNXVLEX-QGZVFWFLSA-N
InChi :
InChI=1S/C27H21FN4O/c1-17(18-9-11-23(28)12-10-18)31-27(33)21-8-4-7-20(13-21)25-16-30-26(32-25)24-14-19-5-2-3-6-22(19)15-29-24/h2-17H,1H3,(H,30,32)(H,31,33)/t17-/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
TTP-8307 is a potent inhibitor of the replication of several rhino- and enteroviruses. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC50=1.2 μM) and poliovirus by interfering with the synthesis of viral RNA. TTP-8307 exerts antiviral activity through oxysterol-binding protein (OSBP).|Product information|CAS Number: 950225-08-8|Molecular Weight: 436.48|Formula: C27H21FN4O|Chemical Name: N-[(1R)-1-(4-fluorophenyl)ethyl]-3-[2-(isoquinolin-3-yl)-1H-imidazol-5-yl]benzamide|Smiles: C[C@@H](NC(=O)C1=CC(=CC=C1)C1=CN=C(N1)C1=CC2=CC=CC=C2C=N1)C1C=CC(F)=CC=1|InChiKey: SIBDJDZVNXVLEX-QGZVFWFLSA-N|InChi: InChI=1S/C27H21FN4O/c1-17(18-9-11-23(28)12-10-18)31-27(33)21-8-4-7-20(13-21)25-16-30-26(32-25)24-14-19-5-2-3-6-22(19)15-29-24/h2-17H,1H3,(H,30,32)(H,31,33)/t17-/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 100 mg/mL (229.{{25-Hydroxycholesterol} web|{25-Hydroxycholesterol} Metabolic Enzyme/Protease|{25-Hydroxycholesterol} Biological Activity|{25-Hydroxycholesterol} In stock|{25-Hydroxycholesterol} manufacturer|{25-Hydroxycholesterol} Cancer} 11 mM; Need ultrasonic).{{Cefotaxime sodium salt} web|{Cefotaxime sodium salt} Beta-lactamase|{Cefotaxime sodium salt} Protocol|{Cefotaxime sodium salt} Data Sheet|{Cefotaxime sodium salt} supplier|{Cefotaxime sodium salt} Autophagy} |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:25027343 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|TTP-8307 targets the nonstructural protein 3A, inhibits the replication of coxsackievirus B3 (CVB3 Nancy) with EC50 of 1.2 μM. TTP-8307 inhibits the replication of coxsackievirus B3 and the three poliovirus Sabin strains, as well as coxsackieviruses A16 and A21 (EC50 of 0.85 and 5.34 μM). TTP-8307 inhibits human rhinoviruses (HRVs) 2, 29, 39, 45, 63, and 85. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. TTP-8307 inhibits OSBP-dependent viruses encephalomyocarditis virus (EMCV) and HCV.|Products are for research use only. Not for human use.|
